RxDoctor Payments Data

Neesha Desai, MD

Child & Adolescent Psychiatry · Decatur, GANPI 1285838516

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 42.0% of the total. 2025 is the largest year on record at $262, 8.8 times the $30 reported in 2023. That places this record below the midpoint for child & adolescent psychiatry clinicians in GA, where the typical reported total is $356.

$307in general payments, 2019–2025

Across 13 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$129
  • Johnson & Johnson$40
  • Neurocrine Biosciences, Inc.$32
  • Tris Pharma Inc$30
  • AbbVie$27
  • Lundbeck LLC$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$307 in reported general payments places this provider in the 40th percentile of 91 child & adolescent psychiatry providers in Georgia.

See all child & adolescent psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$6,234
Medicare patients
16
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$37,008
Olanzapine42$2,032
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate13$1,234
Bupropion Hcl SrBupropion Hcl12$461
Escitalopram Oxalate22$242
Risperidone28$183
Benztropine Mesylate11$174
Zolpidem Tartrate11$55
Lorazepam14$46
Sertraline Hcl11$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$40$37,00820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 91 child & adolescent psychiatry providers in Georgia.

Other child & adolescent psychiatry in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →